Beyond Air Q4 FY26 earnings call XAIR

This was Robert Goodman's first earnings call as CEO, and he framed the company as at a pivotal moment. After months spent with customers, the commercial organization, distribution partners and the board, the leadership team has aligned commercial strategy, R&D and operating expenses around the core LungFit PH business. Capital allocation is now explicitly disciplined: resources are being directed 'almost exclusively' to the LungFit PH system, with programs outside the core de-emphasized. Goodman characterized the setup as an imminent inflection point for revenue growth built on expanding market access, growing customer adoption, international expansion, and the anticipated Gen 2 launch.

Fiscal 2026 revenue of $7.7M more than doubled from $3.7M, driven by demand in both US and international markets, and gross profit reached $0.3M versus a $1.7M loss a year ago — a $2M swing management called a meaningful milestone in operating leverage. The cost side did the heavy lifting: R&D fell 39% to $10.2M on lower employee costs from prior restructuring and reduced Gen 2 development costs after the June 2025 PMA submission, while SG&A fell 27% (~$7M) to $19.1M. The combination drove a $15.5M (35%) improvement in operating results. Offsets included other expense rising to $5.3M from $3.9M; net loss narrowed to $33.2M ($4.01 per share) from $46.6M.

Management attributes the revenue base's stickiness to clinical value and operational service support, and views that satisfaction as directly transposable to Gen 2 — prospective customers are reportedly waiting for the next-generation platform to meet comprehensive nitric oxide requirements including transport. The GPO strategy is central: contracting was structured to get in front of flagship hospital systems immediately so evaluations could begin and, in Goodman's words, 'knock the incumbents out.' Evaluations under the newest GPO are already running, structured as regional pilots within large IDNs that then 'spiderweb' outward. Internationally the company remains early-stage but sees its growing distribution network as a significant future revenue opportunity.

The Gen 2 LungFit PH PMA supplement, filed in June 2025, is the company's most important near-term catalyst, and management describes the FDA as communicative and quick to respond, with the review progressing at the expected pace. Versus the current system — both generate unlimited nitric oxide from room air and offer the fastest speed-to-treatment with start/stop flexibility at the bedside — Gen 2's decisive differences are a fully transport-designed architecture (air and ground) and a far longer field-service interval, which management says benefits both cost of goods and customer device management, alongside a smaller footprint, reduced weight and simplified operation. The current label's exclusion of transport outside the hospital is precisely what has confined the addressable market.

With fiscal 2026 complete, Beyond Air is transitioning from a March 31 to a December 31 fiscal year end and will operate on a calendar-year basis. That transition is the frame for the company's first-ever revenue guidance, given for calendar 2026 and calendar 2027. The Q&A spent considerable time clarifying the basis: the just-reported January-March quarter becomes calendar Q1 2026, calendar 2026 embeds no Gen 2 contribution given the late-year launch assumption, and the step-change year is 2027 when Gen 2 revenue begins flowing in earnest from January.

Earlier in June the NASDAQ hearings panel granted Beyond Air's request for continued listing, conditional on regaining compliance with the minimum bid price requirement. Following stockholder approval at the June 18 special meeting, the board approved a reverse stock split, which management expects will position the company to regain compliance by the panel's deadline. Goodman addressed this proactively in prepared remarks before Q&A, signaling the board views the listing issue as resolved mechanically rather than an open risk.